{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T21:29:52Z","timestamp":1761514192137,"version":"build-2065373602"},"reference-count":47,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2018,7,1]],"date-time":"2018-07-01T00:00:00Z","timestamp":1530403200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,7,1]],"date-time":"2018-07-01T00:00:00Z","timestamp":1530403200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81522045","21702061","17YF1403600","21672064"],"award-info":[{"award-number":["81522045","21702061","17YF1403600","21672064"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012226","name":"Fundamental Research Funds for the Central Universities","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012226","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic & Medicinal Chemistry"],"published-print":{"date-parts":[[2018,7]]},"DOI":"10.1016\/j.bmc.2018.04.037","type":"journal-article","created":{"date-parts":[[2018,4,17]],"date-time":"2018-04-17T22:49:49Z","timestamp":1524005389000},"page":"3117-3125","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"title":["Design, synthesis and evaluation of vilazodone-tacrine hybrids as multitarget-directed ligands against depression with cognitive impairment"],"prefix":"10.1016","volume":"26","author":[{"given":"Wenwen","family":"Liu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaokang","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yixiang","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9212-9826","authenticated-orcid":false,"given":"Jian","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qi","family":"Gong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoxia","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3934-0312","authenticated-orcid":false,"given":"Jin","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fei","family":"Mao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haiyan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jian","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bmc.2018.04.037_b0005","unstructured":"World Health Organization (WHO) website: fact sheet on depression. http:\/\/www.who.int\/mediacentre\/factsheets\/fs369\/en\/. (accessed July 25, 2017)."},{"key":"10.1016\/j.bmc.2018.04.037_b0010","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.ddmec.2004.10.007","article-title":"Mechanisms of depression: the role of neurogenesis","volume":"1","author":"Fritz","year":"2004","journal-title":"Drug Discovery Today: Dis Mech"},{"key":"10.1016\/j.bmc.2018.04.037_b0015","article-title":"Triple reuptake inhibitors as potential therapeutics for depression and other disorders: design paradigm and developmental challenges","author":"Murugaiah","year":"2017","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2018.04.037_b0020","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1002\/j.1875-9114.2012.01121","article-title":"Vilazodone for the treatment of major depressive disorder","volume":"32","author":"Iranikhah","year":"2012","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.bmc.2018.04.037_b0025","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1192\/bjp.176.6.568","article-title":"Depression and risk of cognitive decline and Alzheimer\u2019s disease. Results of two prospective community-based studies in the Netherlands","volume":"176","author":"Geerlings","year":"2000","journal-title":"Br J Psychiatry"},{"key":"10.1016\/j.bmc.2018.04.037_b0030","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1038\/nrn1846","article-title":"New approaches to antidepressant drug discovery: beyond monoamines","volume":"7","author":"Berton","year":"2006","journal-title":"Nat Rev Neurosci"},{"key":"10.1016\/j.bmc.2018.04.037_b0035","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.pharmthera.2005.11.006","article-title":"Multi-target strategies for the improved treatment of depressive states: Conceptual foundations and neuronal substrates, drug discovery and therapeutic application","volume":"110","author":"Millan","year":"2006","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.bmc.2018.04.037_b0040","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1124\/pr.58.2.4","article-title":"Therapeutic targets: progress of their exploration and investigation of their characteristics","volume":"58","author":"Zheng","year":"2006","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.bmc.2018.04.037_b0045","doi-asserted-by":"crossref","first-page":"7280","DOI":"10.1021\/jm200855b","article-title":"Discovery of isoxazole analogues of sazetidine-A as selective \u03b14\u03b22-nicotinic acetylcholinereceptor partial agonists for the treatment of depression","volume":"54","author":"Liu","year":"2001","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2018.04.037_b0050","doi-asserted-by":"crossref","first-page":"6890","DOI":"10.1016\/j.bmc.2009.08.025","article-title":"Inhibition of serotonin and norepinephrine reuptake and inhibition of phosphodiesterase by multi-target inhibitors as potential agents for depression","volume":"17","author":"Cashman","year":"2009","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.bmc.2018.04.037_b0055","doi-asserted-by":"crossref","first-page":"3941","DOI":"10.1016\/j.bmcl.2010.05.008","article-title":"2-Substituted N-aryl piperazines as novel triple reuptake inhibitors for the treatment of depression","volume":"20","author":"Carter","year":"2010","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.bmc.2018.04.037_b0060","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1212\/WNL.59.3.364","article-title":"Depressive symptoms, cognitive decline, and risk of AD in older persons","volume":"59","author":"Wilson","year":"2002","journal-title":"Neurology"},{"key":"10.1016\/j.bmc.2018.04.037_b0065","first-page":"126","article-title":"Depressive symptoms and cognitive decline in a community population of older persons","volume":"75","author":"Wilson","year":"2004","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.bmc.2018.04.037_b0070","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/S2215-0366(16)00012-2","article-title":"Effect of antidepressant treatment on cognitive impairment associated with depression: a randomised longitudinal study","volume":"3","author":"Shilyansky","year":"2016","journal-title":"lancet Psychiatry"},{"key":"10.1016\/j.bmc.2018.04.037_b0075","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1111\/nyas.12669","article-title":"Diagnosis and treatment of depression and cognitive impairment in late life","volume":"1345","author":"Morimoto","year":"2015","journal-title":"Ann NY Acad Sci"},{"key":"10.1016\/j.bmc.2018.04.037_b0080","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1017\/S0033291703008870","article-title":"Treatment response in late-onset depression: relationship to neuropsychological, neuroradiological and vascula rrisk factors","volume":"34","author":"Baldwin","year":"2004","journal-title":"Psychol Med"},{"key":"10.1016\/j.bmc.2018.04.037_b0085","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1001\/archpsyc.57.3.285","article-title":"Executive dysfunction and long-term outcomes of geriatric depression","volume":"57","author":"Alexopoulos","year":"2000","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.bmc.2018.04.037_b0090","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/S0006-3223(02)01348-3","article-title":"Depression in Alzheimer\u2019s disease: overview and treatment","volume":"52","author":"Lyketsos","year":"2002","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.bmc.2018.04.037_b0095","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1176\/ps.50.9.1151","article-title":"The Diagnosis and treatment of depression in dementia","volume":"50","author":"Brian","year":"1999","journal-title":"Psychiatr Serv"},{"key":"10.1016\/j.bmc.2018.04.037_b0100","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.3233\/JAD-2010-100153","article-title":"Depression in Alzheimer\u2019s disease. Pathophysiology, diagnosis, and treatment","volume":"21","author":"Modrego","year":"2010","journal-title":"J Alzheimer's Dis"},{"key":"10.1016\/j.bmc.2018.04.037_b0105","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1177\/1533317510382286","article-title":"Patterns of cognitive decline, conversion rates, and predictive validity for 3 models of MCI","volume":"25","author":"Ritchie","year":"2010","journal-title":"Am J Alzheimer\u2019s Dis Other Demen"},{"key":"10.1016\/j.bmc.2018.04.037_b0110","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/j.neuroscience.2006.08.041","article-title":"The involvement of cholinergic and noradrenergic systems inbehavioral recovery following oxotremorine treatment to chronically stressed rats","volume":"143","author":"Srikumar","year":"2006","journal-title":"Neuroscience"},{"key":"10.1016\/j.bmc.2018.04.037_b0115","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.nlm.2003.07.003","article-title":"Acetylcholine modulation of neural systems involved in learning and memory","volume":"80","author":"Gold","year":"2003","journal-title":"Neurobiol Learn Mem"},{"key":"10.1016\/j.bmc.2018.04.037_b0120","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.brainres.2008.07.090","article-title":"Increasing hippocampal acetylcholine levels enhance behavioral performance in an animal model of diencephalic amnesia","volume":"1234","author":"Roland","year":"2008","journal-title":"Brain Res"},{"key":"10.1016\/j.bmc.2018.04.037_b0125","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.bmc.2017.11.033","article-title":"Anjali, Sharma A, Silakari P. Design, synthesis and pharmacological evaluation of some novel indanone derivatives asacetylcholinesterase inhibitors for the management of cognitive dysfunction","volume":"26","author":"Piplani","year":"2018","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.bmc.2018.04.037_b0130","doi-asserted-by":"crossref","first-page":"349","DOI":"10.3233\/JAD-122140","article-title":"A meta-analysis of the efficacy of donepezil, rivastigmine, galantamine, and memantine in relation to severity of Alzheimer's disease","volume":"35","author":"Di Santo","year":"2013","journal-title":"J Alzheimer's Dis"},{"key":"10.1016\/j.bmc.2018.04.037_b0135","doi-asserted-by":"crossref","first-page":"2323","DOI":"10.1161\/01.STR.0000091396.95360.E1","article-title":"The Donepezil 307 Vascular Dementia Study Group. Efficacy and tolerability of donepezil in vascular dementia positive results of a 24-week, multicenter, international, randomized, placebo-controlled clinical trial","volume":"34","author":"Black","year":"2003","journal-title":"Stroke"},{"key":"10.1016\/j.bmc.2018.04.037_b0140","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1016\/S1474-4422(07)70195-3","article-title":"Efficacy and adverse effects of cholinesterase inhibitors and memantine in vascular dementia: a meta-analysis of randomised controlled trials","volume":"6","author":"Kavirajan","year":"2007","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.bmc.2018.04.037_b0145","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.cct.2013.11.015","article-title":"Donepezil treatment of older adults with cognitive impairment and depression (DOTCODEstudy): clinical rationale and design","volume":"37","author":"Pelton","year":"2014","journal-title":"Contemp Clin Trials"},{"key":"10.1016\/j.bmc.2018.04.037_b0150","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1345\/aph.1Q445","article-title":"Cholinesterase inhibitor adjunctive therapy for cognitive impairment and depressive symptoms in older adults with depression","volume":"46","author":"McDermott Cara","year":"2012","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.bmc.2018.04.037_b0155","doi-asserted-by":"crossref","first-page":"1886","DOI":"10.1016\/j.drudis.2016.08.001","article-title":"Multi-target therapeutics for neuropsychiatric and neurodegenerative disorders","volume":"21","author":"Bawa","year":"2016","journal-title":"Drug Discovery Today"},{"key":"10.1016\/j.bmc.2018.04.037_b0160","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1254\/jphs.93.95","article-title":"Pharmacological characterization of RS-1259, an orally active dual inhibitor of acetylcholinesterase and serotonin transporter, in rodents: possible treatment of Alzheimer\u2019s disease","volume":"93","author":"Abe","year":"2003","journal-title":"J Pharmacol Sci"},{"key":"10.1016\/j.bmc.2018.04.037_b0165","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1016\/S0968-0896(03)00091-9","article-title":"Design, synthesis and structure-activity relationships of dual inhibitors of acetylcholinesterase and serotonin transporter as potential agents for Alzheimer\u2019s disease","volume":"11","author":"Toda","year":"2003","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.bmc.2018.04.037_b0170","doi-asserted-by":"crossref","first-page":"615","DOI":"10.2165\/11207550-000000000-00000","article-title":"Vilazodone: In major depressive disorder","volume":"25","author":"James","year":"2011","journal-title":"CNS Drugs"},{"key":"10.1016\/j.bmc.2018.04.037_b0175","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1021\/cr078224o","article-title":"Serotonin receptors","volume":"108","author":"Nichols","year":"2008","journal-title":"Chem Rev"},{"key":"10.1016\/j.bmc.2018.04.037_b0180","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1111\/j.1530-0277.2001.tb02240.x","article-title":"Serotonergic dysfunction, negative mood states, and response to alcohol","volume":"25","author":"Heinz","year":"2001","journal-title":"Clin Exp Res"},{"key":"10.1016\/j.bmc.2018.04.037_b0185","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.pneurobio.2009.01.009","article-title":"5-HT1A receptor function in major depressive disorder","volume":"88","author":"Savitz","year":"2009","journal-title":"Prog Neurobiol"},{"key":"10.1016\/j.bmc.2018.04.037_b0190","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1007\/BF02244228","article-title":"Antidepressant-like activity of 5-HT1A agonists measured with the forced swim test","volume":"101","author":"Wieland","year":"1990","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.bmc.2018.04.037_b0195","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/S0006-3223(02)01643-8","article-title":"Is there a role for 5-HT1A agonists in the treatment of depression?","volume":"53","author":"Blier","year":"2003","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.bmc.2018.04.037_b0200","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1016\/j.ajog.2016.07.011","article-title":"Selective serotonin reuptake inhibitors for depression in pregnancy","volume":"215","author":"Susser","year":"2016","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.bmc.2018.04.037_b0205","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/S0278-5846(02)00338-X","article-title":"Role of selective serotonin reuptake inhibitors in psychiatric disorders:a comprehensive review","volume":"27","author":"Vaswani","year":"2003","journal-title":"Prog Neuro-Psychopharmacol Biol Psychiatry"},{"key":"10.1016\/j.bmc.2018.04.037_b0210","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/S0163-7258(99)00048-0","article-title":"Pharmacokinetics of selective serotonin reuptake inhibitors","volume":"85","author":"Hiemke","year":"1999","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.bmc.2018.04.037_b0215","doi-asserted-by":"crossref","first-page":"4677","DOI":"10.1021\/jm040792y","article-title":"Indolebutylamines as selective 5-HT1A agonists","volume":"47","author":"Heinrich","year":"2004","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2018.04.037_b0220","doi-asserted-by":"crossref","first-page":"4684","DOI":"10.1021\/jm040793q","article-title":"Synthesis and structure-activity relationship in a class of indolebutylpiperazines as dual 5-HT1A receptor agonists and serotonin reuptake inhibitors","volume":"47","author":"Heinrich","year":"2004","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2018.04.037_b0225","doi-asserted-by":"crossref","first-page":"2708","DOI":"10.1021\/acschemneuro.7b00259","article-title":"Novel vilazodone-tacrine hybrids as potential multitarget-directed ligands for the treatment of Alzheimer\u2019s disease accompanied with depression: design, synthesis and biological evaluation","volume":"8","author":"Li","year":"2017","journal-title":"ACS Chem Neurosci"},{"key":"10.1016\/j.bmc.2018.04.037_b0230","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/0006-2952(61)90145-9","article-title":"A new and rapid colorimetric determination of acetylcholinesterase activity","volume":"7","author":"Ellman","year":"1961","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.bmc.2018.04.037_b0235","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S0223-5234(03)00012-6","article-title":"High throughput artificial membrane permeability assay for blood-brain barrier","volume":"38","author":"Di","year":"2003","journal-title":"Eur J Med Chem"}],"container-title":["Bioorganic & Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0968089618302360?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0968089618302360?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T00:54:50Z","timestamp":1760835290000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0968089618302360"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7]]},"references-count":47,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2018,7]]}},"alternative-id":["S0968089618302360"],"URL":"https:\/\/doi.org\/10.1016\/j.bmc.2018.04.037","relation":{},"ISSN":["0968-0896"],"issn-type":[{"type":"print","value":"0968-0896"}],"subject":[],"published":{"date-parts":[[2018,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Design, synthesis and evaluation of vilazodone-tacrine hybrids as multitarget-directed ligands against depression with cognitive impairment","name":"articletitle","label":"Article Title"},{"value":"Bioorganic & Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bmc.2018.04.037","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}